Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Nikos, Giannakoulas"'
Autor:
Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Sosana Delimpasi, Emmanouil Spanoudakis, Vasiliki Labropoulou, Ioannis Ntanasis‐Stathopoulos, Annita‐Ioanna Gkioka, Nikos Giannakoulas, Nikolaos Kanellias, Theodosia Papadopoulou, Aggeliki Sevastoudi, Eyrydiki Michalis, Maria Papathanasiou, Maria Kotsopoulou, Anastasia Sioni, Theodora Triantafyllou, Aikaterini Daiou, Mavra Papadatou, Marie‐Christine Kyrtsonis, Anastasia Pouli, Ioannis Kostopoulos, Evgenia Verrou, Meletios‐Athanasios Dimopoulos, Evangelos Terpos
Publikováno v:
American Journal of Hematology. 98:730-738
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9380d9ded7c86334e0b5ffda266fcdc
https://doi.org/10.1002/ajh.26891
https://doi.org/10.1002/ajh.26891
Autor:
Charikleia Kelaidi, Marie-Christine Kyrtsonis, Sossana Delimpasi, Evgenia Verrou, Nikos Giannakoulas, Pavlina Konstantinidou, Eirini Katodritou, Maria Kotsopoulou, Kostas Zervas, Argiris Symeonidis, Christina Chatziaggelidou, Evangelos Terpos, Aikaterini Stefanoudaki, Nikos Spyridis, Meletios A. Dimopoulos, Vassiliki Gastari, Dimitrios Christoulas
Publikováno v:
American Journal of Hematology. 89:145-150
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety in PCL. Thus, we retrospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc172667bad44330c6cc0504c952a89a
https://doi.org/10.1002/ajh.23600
https://doi.org/10.1002/ajh.23600
Autor:
Eirini, Katodritou, Evangelos, Terpos, Charikleia, Kelaidi, Maria, Kotsopoulou, Sossana, Delimpasi, Marie-Christine, Kyrtsonis, Argiris, Symeonidis, Nikos, Giannakoulas, Aikaterini, Stefanoudaki, Dimitrios, Christoulas, Christina, Chatziaggelidou, Vassiliki, Gastari, Nikos, Spyridis, Evgenia, Verrou, Pavlina, Konstantinidou, Kostas, Zervas, Meletios A, Dimopoulos
Publikováno v:
American journal of hematology. 89(2)
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety in PCL. Thus, we retrospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::179b1b80297b9e56e6566ed57d218acb
https://pubmed.ncbi.nlm.nih.gov/24123068
https://pubmed.ncbi.nlm.nih.gov/24123068